^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FAAH inhibitor

    Related drugs:
    7ms
    Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (clinicaltrials.gov)
    P2, N=120, Recruiting, Celgene | Not yet recruiting --> Recruiting
    Enrollment open
    7ms
    MSS: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity (clinicaltrials.gov)
    P2, N=200, Recruiting, Celgene | Not yet recruiting --> Recruiting
    Enrollment open
    9ms
    Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Celgene | Trial completion date: May 2027 --> Sep 2027 | Trial primary completion date: Mar 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    10ms
    EICAS: Evaluation Study of New Compounds with Potential Use in Schizophrenia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Central Institute of Mental Health, Mannheim | N=86 --> 0 | Trial completion date: Dec 2022 --> Jan 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2022 --> Jan 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    11ms
    A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder (clinicaltrials.gov)
    P2, N=150, Completed, Janssen Research & Development, LLC | Phase classification: P2a --> P2
    Phase classification
    12ms
    Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Celgene
    New P2 trial
    12ms
    An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress (clinicaltrials.gov)
    P2, N=161, Completed, Janssen Research & Development, LLC | Phase classification: P2a --> P2
    Phase classification
    12ms
    MSS: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Celgene
    New P2 trial
    1year
    FAAH Inhibition Reverses Depressive-like Behavior and Sex-Specific Neuroinflammatory Alterations Induced by Early Life Stress. (PubMed, Cells)
    Some of these effects began in late adolescence, including mPFC-nfκb1 expression in both sexes, mPFC-il6 and mPFC-il1β in females, CA1-il1β and CA1-tnfα in males, and CA1-il1β in females. These findings highlight URB597 as a therapeutic approach for reversing ELS-induced depressive-like behavior by associating with changes in the gene expression of neuroinflammatory cytokines, with notable sex differences.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    IL6 expression
    1year
    A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity (clinicaltrials.gov)
    P1, N=56, Completed, Celgene | Recruiting --> Completed
    Trial completion
    over1year
    Mitigation of cisplatin-induced acute kidney injury through oral administration of FAAH Inhibitor PF-04457845. (PubMed, J Pharmacol Exp Ther)
    Significance Statement Oral administration of FAAH inhibitor, can reduce cisplatin-induced DNA damage response, tubular damages, and kidney dysfunction. Inactivation of FAAH could be a potential strategy to prevent cisplatin-induced nephrotoxicity.
    Journal
    |
    KIM1 (Kidney injury molecule 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    cisplatin
    over1year
    IM045-1002: A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Completed, Celgene | Recruiting --> Completed
    Trial completion
    |
    itraconazole